Ista Pharmaceuticals — Investor Presentation (December 2011)
24 slides from Ista Pharmaceuticals's investor presentation, Dec 22, 2011
Slide 1: Investor Presentation December 2011
Exhibit 99.1 Investor Presentation December 2011
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied
Slide 3: Company Timeline
Company Timeline BROMDAY™ XIBROM™ BEPREVE® ISTALOL® VITRASE® 1992 2000 2002 2004 2005 2009 2010 Acquired ISTALOL & XIBROM Revenue ISTA >$100 million Profitable* Name change to ISTA Pharmaceuticals, Inc. IPO on NASDAQ Founded as Advanced Corneal Systems * On an adjusted cash net income basis ISTA PHA
Slide 4: ISTA's Track Record of Success
ISTA’s Track Record of Success • Thriving core Rx eye business, emerging Rx allergy franchise – Third largest branded Rx eye care company in U.S. • Obtained 5 Rx eye and allergy product approvals in 6 years – ISTALOL, VITRASE, XIBROM, BEPREVE, BROMDAY – Products are #1 or #2 in their markets with ma
Slide 5: 2011 – Solid Commercial and Pipeline Progress
2011 – Solid Commercial and Pipeline Progress • Highly successful switch from XIBROM to BROMDAY • BEPREVE projected to increase significantly over 2010 • Strong pipeline progress, de-risking of programs – PROLENSA™ Phase 3 successful – BEPOMAX™ Phase 2 successful, BEPOSONE™ to enter Phase 2 shortly
Slide 6: Current Commercial Products
Current Commercial Products $300 Million Mid-Term Potential Revenue BROMDAY™ BEPREVE® Only once-daily Fast growing, twice-daily prescription eye drop for prescription eye drop for postoperative ocular itching associated inflammation and with allergic conjunctivitis reduction of ocular pain in patien
Slide 7: BROMDAY
BROMDAY TM Convenient Once-Daily Dosing The ONLY approved once-daily Rx non-steroidal anti-inflammatory (NSAID) eye drop for pain and inflammation post-cataract surgery • BROMDAY October 2011 prescriptions EstimatedNSAID2011MarketSizeTRx$: ~$367MM equal to highest level achieved by Based on Nov 2011
Slide 8: BROMDAY Outlook Strong
BROMDAY Outlook Strong Prescription Dollars Reflect Increasing Average Price 35.0% BROMDAY Market Shares 33% 30.0% #1 in Total Prescription Dollars (TRx$) 25.0% 24% Achieved 33% TRx$ share in 20.0% only 13 months 15.0% 10.0% 5.0% 0.0% Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-11 Ju
Slide 9: BEPREVE
BEPREVE ® Near-term tactical drivers in place Opportunity for BEPREVE to gain additional market share • Twice-daily antihistamine eye drop to treat 2011EstimatedAllergyMarket: ~$780MM itching associated with allergic conjunctivitis Nov 2011 Rolling 12 Month TRx • Projected 2011 revenues to grow sign
Slide 10: ISTALOL and VITRASE
ISTALOL and VITRASE Established base products • ISTALOL – Market-leading once daily beta-blocker eye drop for glaucoma – Growth through share gain and pricing – 2010 market size: ~$ 180 million – Patent protection to 2018 • VITRASE – Injectable biologic spreading agent, hyaluronidase, used to enhanc
Slide 11: ISTA's Robust Near-Term Pipeline
ISTA’s Robust Near-Term Pipeline Launches Drive Revenues to $500 by 2015* Formulation Phase 1 Phase 2 Phase 3 2015 Est. Candidates** Market Size OTC eye products Dry eye $300 million PROLENSA Ocular Inflammation & Pain $500+ million Low-concentration bromfenac T-PRED Ocular Inflammation / Infection
Slide 12: OTC Eye Products
OTC Eye Products Expansion of Rx Business into High- Operating Margin Consumer Cash Business Existing sales force to drive practitioner-recommended sales • Over-the-Counter eye drops for treatment of dry eye and other ocular conditions • OTC developed and tested in 2011 during prescription dry eye P
Slide 13: PROLENSA
PROLENSA ™ New Formula with Pending Patents through 2024 Key extension of successful bromfenac business • Bromfenac-based NSAID for ocular pain and inflammation associatedwith cataractextraction– projectedto replaceBROMDAY • PositivePhase3 StudyResultsReportedOct.2011– Clinicalwork done – Lowest num
Slide 14: T-Pred
T-Pred Promising Anti-Infective/Steroid Ideal supplemental product to leverage sales infrastructure • Fixed combination prednisolone & tobramycin prescription eye drop • For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocul
Slide 15: BEPOMAX
BEPOMAX Major Extension of Allergy Franchise Large Market Opportunity Exists 2015 Potential: ~$400+ million • Single agent antihistamine nasal spray • Active ingredient, bepotastine, already approved in Rx eye drop BEPREVE • For treatment of seasonal allergic rhinitis • Positive Phase 2 Study result
Slide 16: BEPOSONE
BEPOSONE ™ "Holy-Grail" Rx Nasal Allergy Product Large Market Opportunity Exists 2015 Potential: $2+ Billion • Combination patented antihistamine / steroid • Antihistamine, bepotastine, already approved in Rx eye drop BEPREVE • For treatment of seasonal allergic rhinitis • Filed Investigational New
Slide 17: Bromfenac Adjunct for AMD
Bromfenac Adjunct for AMD Lower-Risk "Back of the Eye" Approach Continued growth of successful bromfenac franchise • Higher-concentration, new formulation of bromfenac • For adjunctive treatment of age-related macular degeneration (AMD) • Paper published in Sept 2011 Issue of RETINA suggests bromfen
Slide 18: ISTA's Key Patents and Applications
ISTA’s Key Patents and Applications PRODUCT(S) PATENT(S) AND EXPIRATION KEY CLAIM(S) BEPREVE ISSUED Bepotastine API and methods of mfg. (composition of matter for Exp: Dec 2017 , filed for extension to Sept 2019 Bepotastine besilate) BEPOSONE APPLICATION Aqueous formulation Estimated Exp: July 2023
Slide 19: ISTA Strategy for Long-Term Success
ISTA Strategy for Long-Term Success Marketed Product Business Products Pipeline Development • PROLENSA (low- • Acquire marketed products concentration bromfenac) • License late stage assets • T-PRED in 2013+ BROMDAY ISTALOL VITRASE • BEPOMAX nasal spray • Acquire marketed products • BEPOSONE combo •
Slide 20: Business Development
Business Development External Value Creation • Disciplined approach to evaluation of opportunities • Rx Eye and Rx Allergy for growth and commercial synergy – Acquire marketed or soon-to-be marketed products – License late-stage products – Partner for access to primary care physicians and consumer b
Slide 21: ISTA: Fast-Growing, Niche Pharmaceutical Company
ISTA Fast-Growing, Niche Pharmaceutical Company Outlook$160 –$175 ISTA PHARMACEUTICALS 21
Slide 22: 2012 Guidance and Pipeline Update
2012 Guidance and Pipeline Update • WebcastandConferencecall – Jan.4, 2012 4:30 pm ET – Internet: http://www.istavision.com/investors.html – Domestic dial-in: 866-270-6057 International : 617-213-8891 – Passcode: 58694464 ISTA PHARMACEUTICALS 22
Slide 23: Realizing Value - Looking to 2015 and Beyond
Realizing Value - Looking to 2015 and Beyond • "5 in 5" – 5 new product launches in next 5 years • Rx Eye, Rx Allergy, Over-the-Counter – $500 million in revenues by 2015 • Forecasted compounded 5-year revenue growth rate ~ 40% • Organic growth from current products drives revenues majority growth o
Slide 24: A Pharmaceuticals’
A Pharmaceuticals’
Ista Pharmaceuticals — Investor Presentation (December 2011) on 6ix